Literature DB >> 28885271

Isoniazid Preventive Therapy Completion in the Era of Differentiated HIV Care.

Khai Hoan Tram1, Florence Mwangwa, Mucunguzi Atukunda, Asiphas Owaraganise, James Ayieko, Albert Plenty, Dalsone Kwariisima, Tamara D Clark, Maya L Petersen, Edwin D Charlebois, Moses R Kamya, Gabriel Chamie, Diane V Havlir, Carina Marquez.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28885271      PMCID： PMC5680115          DOI： 10.1097/QAI.0000000000001540

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  17 in total

1.  Loss to follow up from isoniazid preventive therapy among adults attending HIV voluntary counseling and testing sites in Uganda.

Authors:  P M Namuwenge; J K Mukonzo; N Kiwanuka; R Wanyenze; R Byaruhanga; K Bissell; R Zachariah
Journal:  Trans R Soc Trop Med Hyg       Date:  2011-12-10       Impact factor: 2.184

2.  Implementation and Operational Research: Declining Tuberculosis Incidence Among People Receiving HIV Care and Treatment Services in East Africa, 2007-2012.

Authors:  Suzue Saito; Philani Mpofu; E Jane Carter; Lameck Diero; Kara K Wools-Kaloustian; Constantin T Yiannoutsos; Musick S Beverly; Simon Tsiouris; Geoffrey R Somi; John Ssali; Denis Nash; Batya Elul
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-01       Impact factor: 3.731

3.  High completion of isoniazid preventive therapy among HIV-infected children and adults in Kinshasa, Democratic Republic of Congo.

Authors:  Marcel Yotebieng; Andrew Edmonds; Patricia Lelo; Landry Kipula Wenzi; Papy Tshishikani Ndjibu; Jean Lusiama; Jean Pierre Kabuayi; Frieda Behets
Journal:  AIDS       Date:  2015-09-24       Impact factor: 4.177

4.  Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials.

Authors:  H C Bucher; L E Griffith; G H Guyatt; P Sudre; M Naef; P Sendi; M Battegay
Journal:  AIDS       Date:  1999-03-11       Impact factor: 4.177

5.  Tuberculosis case finding and preventive therapy in an HIV voluntary counseling and testing center in Uganda.

Authors:  B Mugisha; N Bock; J Mermin; R M Odeke; B Miller; F Adatu-Engwau; R Granich; R Bunnell
Journal:  Int J Tuberc Lung Dis       Date:  2006-07       Impact factor: 2.373

Review 6.  Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature.

Authors:  Melissa A Briggs; Courtney Emerson; Surbhi Modi; Nicholas Kenji Taylor; Anand Date
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

7.  Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania.

Authors:  P J Munseri; E A Talbot; L Mtei; C Fordham von Reyn
Journal:  Int J Tuberc Lung Dis       Date:  2008-09       Impact factor: 2.373

8.  High rates of viral suppression in adults and children with high CD4+ counts using a streamlined ART delivery model in the SEARCH trial in rural Uganda and Kenya.

Authors:  Dalsone Kwarisiima; Moses R Kamya; Asiphas Owaraganise; Florence Mwangwa; Dathan M Byonanebye; James Ayieko; Albert Plenty; Doug Black; Tamara D Clark; Bridget Nzarubara; Katherine Snyman; Lillian Brown; Elizabeth Bukusi; Craig R Cohen; Elvin H Geng; Edwin D Charlebois; Theodore D Ruel; Maya L Petersen; Diane Havlir; Vivek Jain
Journal:  J Int AIDS Soc       Date:  2017-07-21       Impact factor: 5.396

9.  Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study.

Authors:  David M Tuller; David R Bangsberg; Jude Senkungu; Norma C Ware; Nneka Emenyonu; Sheri D Weiser
Journal:  AIDS Behav       Date:  2009-03-13

10.  A hybrid mobile approach for population-wide HIV testing in rural east Africa: an observational study.

Authors:  Gabriel Chamie; Tamara D Clark; Jane Kabami; Kevin Kadede; Emmanuel Ssemmondo; Rachel Steinfeld; Geoff Lavoy; Dalsone Kwarisiima; Norton Sang; Vivek Jain; Harsha Thirumurthy; Teri Liegler; Laura B Balzer; Maya L Petersen; Craig R Cohen; Elizabeth A Bukusi; Moses R Kamya; Diane V Havlir; Edwin D Charlebois
Journal:  Lancet HIV       Date:  2016-01-26       Impact factor: 12.767
View more
  4 in total

1.  Predictors of isoniazid preventive therapy completion among HIV-infected patients receiving differentiated and non-differentiated HIV care in rural Uganda.

Authors:  Khai Hoan Tram; Florence Mwangwa; Gabriel Chamie; Mucunguzi Atukunda; Asiphas Owaraganise; James Ayieko; Vivek Jain; Tamara D Clark; Dalsone Kwarisiima; Maya L Petersen; Moses R Kamya; Edwin D Charlebois; Diane V Havlir; Carina Marquez
Journal:  AIDS Care       Date:  2019-06-10

2.  Determinants of isoniazid preventive therapy completion among people living with HIV attending care and treatment clinics from 2013 to 2017 in Dar es Salaam Region, Tanzania. A cross-sectional analytical study.

Authors:  Masanja Robert; Jim Todd; Bernard J Ngowi; Sia E Msuya; Angella Ramadhani; Veryhel Sambu; Isaya Jerry; Martin R Mujuni; Michael J Mahande; James S Ngocho; Werner Maokola
Journal:  BMC Infect Dis       Date:  2020-04-10       Impact factor: 3.090

3.  Cost-effectiveness of scaling up short course preventive therapy for tuberculosis among children across 12 countries.

Authors:  Youngji Jo; Isabella Gomes; Joseph Flack; Nicole Salazar-Austin; Gavin Churchyard; Richard E Chaisson; David W Dowdy
Journal:  EClinicalMedicine       Date:  2021-01-07

4.  A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.

Authors:  Simon Sensalire; Esther Karungi Karamagi Nkolo; Juliana Nabwire; Anna Lawino; Dithan Kiragga; Martin Muhire; Herbert Kadama; Cordelia Katureebe; Proscovia Namuwenge; Joshua Musinguzi; Jacqueline Calnan; Dejene Seyoum
Journal:  AIDS Res Ther       Date:  2020-05-27       Impact factor: 2.250
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.